Browsing Enfermedades Desmielinizantes.pósters by Subject "Ofatumumab"

Now showing items 1-2 of 2

Baseline Characteristics of Patients with Relapsing Multiple Sclerosis in ASCLEPIOS Phase 3 Trials of Ofatumumab Versus Teriflunomide (P3.2-096)

Kappos, Ludwig; Bar-Or, Amit; Cohen, Jeffrey A.; Comi, Giancarlo; Correale, Jorge; Coyle, Patricia K.; Cross, Anne H.; de Seze, Jerome; Montalban, Xavier; Selmaj, Krzysztof; Wiendl, Heinz; Leppert, David; Kerloeguen, Cecile; Willi, Roman; Häring, Dieter A.; Tomic, Davorka; Goodyear, Alexandra; Merschhemke, Martin; Hauser, Stephen L. (Lippincott Williams & Wilkins, 2019-04-16)

Objective: To present the baseline characteristics of patients enrolled in the ASCLEPIOS I and II trials. Background: ASCLEPIOS I and II are two Phase 3 trials of identical design that are being conducted simultaneously ...
Effect of Ofatumumab on Serum Immunoglobulin Levels and Infection Risk in Patients With Relapsing Multiple Sclerosis Over 3.5 Years

Wiendl, Heinz; de Seze, Jerome; Bar-Or, Amit; Correale, Jorge; Cross, Anne H.; Kappos, Ludwig; Selmaj, Krzysztof; Winthrop, Kevin; Giacomini, Paul Steven; Sacca, Francesco; Das Gupta, Ayan; Jehl, Valentine; Pingili, Ratnakar; Mancione, Linda; Zielman, Ronald; Hauser, Stephen L. (37th Congress of the European Committee for Treatment and Research in Multiple Sclerosis, 2021-10)

Resumen no disponible

Search DSpace